Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

Abstract Introduction Patients with advanced non-small cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Biomarkers such as programmed death-ligand 1 (PD-L1), the tumor mutational burden (TMB) and the mismatch repair (MMR) status are used to predict the progno...

Full description

Bibliographic Details
Main Authors: Dantong Sun, Lu Tian, Yan Zhu, Yang Wo, Qiaoling Liu, Shihai Liu, Hong Li, Helei Hou
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Molecular Medicine
Subjects:
ARID1A
ARID1B
NSCLC
Immune checkpoint inhibitors
Prognosis
Online Access:http://link.springer.com/article/10.1186/s10020-020-00208-9

Internet

http://link.springer.com/article/10.1186/s10020-020-00208-9

Similar Items